Skip to main content
PMC home page
British Journal of Pharmacology logoLink to British Journal of Pharmacology
. 1995 Nov;116(5):2391–2400. doi: 10.1111/j.1476-5381.1995.tb15085.x

Comparison between novel steroid-like and conventional nonsteroidal antioestrogens in inhibiting oestradiol- and IGF-I-induced proliferation of human breast cancer-derived cells.

A de Cupis 1, D Noonan 1, P Pirani 1, A Ferrera 1, L Clerico 1, R E Favoni 1
PMCID: PMC1909063  PMID: 8581274

Abstract

1. This study has two specific aims: (a) to compare the antioestrogenic activity of two steroidal analogues of 17 beta-oestradiol, the 7 alpha-alkylamide, ICI 164,384 and the 7 alpha-alkylsulphinylamide, ICI 182,780, with that of the triphenylethylene-derived compound 4OH-tamoxifen on a pool of human breast cancer cell lines (HBCCL) with a range of hormonal responsiveness and acquired anti-oestrogen resistance and (b) to investigate the ability of such antioestrogens to modulate the potent breast carcinoma growth-stimulatory activity of the 'IGF-I system'. 2. For the chemosensitivity investigations we used a long-term colorimetric and the short-term thymidine incorporation assay; we analysed IGF-I in conditioned media by a radioimmunoassay, IGF-I mRNA in the cells by RT-PCR and molecular species of IGF-I-binding proteins, secreted in conditioned media, by Western ligand blot. IGF-I receptors were assayed on cell monolayers by binding studies and by Scatchard analysis, we calculated KD, Bmax and sites/cell. 3. Our results indicate that ICI 182,780 and ICI 164,384 are 1.5-5.5 fold more potent than 4OH-tamoxifen in inhibiting the basal proliferation of oestrogen-receptor positive (ER+) breast cancer cell lines. Moreover we demonstrate the capacity of ICI 182,780 and ICI 164,384 to reduce, in a time-dependent fashion, oestrogen- and/or IGF-I-stimulated growth of ER+cell lines, possibly by negatively interfering with an IGF-I-like material secretion and IGF-I-receptor number. 4. Our data provide the first evidence that, on ER+human breast carcinoma cell lines, steroidal antioestrogens inhibit cell growth and modulate the IGF-I mitogenic system. The mechanism of this latter effect has yet to be identified.

Full text

PDF
2391

Images in this article

2394Figure 1
on p.2394
2395Figure 2
on p.2395
2396Figure 3
on p.2396
2397Figure 4
on p.2397

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bates S. E., Davidson N. E., Valverius E. M., Freter C. E., Dickson R. B., Tam J. P., Kudlow J. E., Lippman M. E., Salomon D. S. Expression of transforming growth factor alpha and its messenger ribonucleic acid in human breast cancer: its regulation by estrogen and its possible functional significance. Mol Endocrinol. 1988 Jun;2(6):543–555. doi: 10.1210/mend-2-6-543. [DOI] [PubMed] [Google Scholar]
  2. Bowler J., Lilley T. J., Pittam J. D., Wakeling A. E. Novel steroidal pure antiestrogens. Steroids. 1989 Jul;54(1):71–99. doi: 10.1016/0039-128x(89)90076-7. [DOI] [PubMed] [Google Scholar]
  3. Carmichael J., DeGraff W. G., Gazdar A. F., Minna J. D., Mitchell J. B. Evaluation of a tetrazolium-based semiautomated colorimetric assay: assessment of chemosensitivity testing. Cancer Res. 1987 Feb 15;47(4):936–942. [PubMed] [Google Scholar]
  4. Caron de Fromentel C., Nardeux P. C., Soussi T., Lavialle C., Estrade S., Carloni G., Chandrasekaran K., Cassingena R. Epithelial HBL-100 cell line derived from milk of an apparently healthy woman harbours SV40 genetic information. Exp Cell Res. 1985 Sep;160(1):83–94. doi: 10.1016/0014-4827(85)90238-1. [DOI] [PubMed] [Google Scholar]
  5. Controlled trial of tamoxifen as a single adjuvant agent in the management of early breast cancer. 'Nolvadex' Adjuvant Trial Organisation. Br J Cancer. 1988 Jun;57(6):608–611. doi: 10.1038/bjc.1988.138. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Cullen K. J., Yee D., Bates S. E., Brunner N., Clarke R., Dickson R. E., Huff K. K., Paik S., Rosen N., Valverius E. Regulation of human breast cancer by secreted growth factors. Acta Oncol. 1989;28(6):835–839. doi: 10.3109/02841868909092318. [DOI] [PubMed] [Google Scholar]
  7. De Leon D. D., Bakker B., Wilson D. M., Lamson G., Rosenfeld R. G. Insulin-like growth factor binding proteins in human breast cancer cells: relationship to hIGFBP-2 and hIGFBP-3. J Clin Endocrinol Metab. 1990 Aug;71(2):530–532. doi: 10.1210/jcem-71-2-530. [DOI] [PubMed] [Google Scholar]
  8. DeFriend D. J., Howell A., Nicholson R. I., Anderson E., Dowsett M., Mansel R. E., Blamey R. W., Bundred N. J., Robertson J. F., Saunders C. Investigation of a new pure antiestrogen (ICI 182780) in women with primary breast cancer. Cancer Res. 1994 Jan 15;54(2):408–414. [PubMed] [Google Scholar]
  9. Elgin R. G., Busby W. H., Jr, Clemmons D. R. An insulin-like growth factor (IGF) binding protein enhances the biologic response to IGF-I. Proc Natl Acad Sci U S A. 1987 May;84(10):3254–3258. doi: 10.1073/pnas.84.10.3254. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Favoni R. E., de Cupis A., Ravera F., Cantoni C., Pirani P., Ardizzoni A., Noonan D., Biassoni R. Expression and function of the insulin-like growth factor I system in human non-small-cell lung cancer and normal lung cell lines. Int J Cancer. 1994 Mar 15;56(6):858–866. doi: 10.1002/ijc.2910560618. [DOI] [PubMed] [Google Scholar]
  11. Freiss G., Prebois C., Rochefort H., Vignon F. Anti-steroidal and anti-growth factor activities of anti-estrogens. J Steroid Biochem Mol Biol. 1990 Dec 20;37(6):777–781. doi: 10.1016/0960-0760(90)90419-l. [DOI] [PubMed] [Google Scholar]
  12. Friedl A., Jordan V. C., Pollak M. Suppression of serum insulin-like growth factor-1 levels in breast cancer patients during adjuvant tamoxifen therapy. Eur J Cancer. 1993;29A(10):1368–1372. doi: 10.1016/0959-8049(93)90003-x. [DOI] [PubMed] [Google Scholar]
  13. Furlanetto R. W., Marino J. M. Radioimmunoassay of somatomedin C/insulin-like growth factor I. Methods Enzymol. 1987;146:216–226. doi: 10.1016/s0076-6879(87)46023-0. [DOI] [PubMed] [Google Scholar]
  14. Gong Y., Ballejo G., Murphy L. C., Murphy L. J. Differential effects of estrogen and antiestrogen on transforming growth factor gene expression in endometrial adenocarcinoma cells. Cancer Res. 1992 Apr 1;52(7):1704–1709. [PubMed] [Google Scholar]
  15. Howell A., DeFriend D., Robertson J., Blamey R., Walton P. Response to a specific antioestrogen (ICI 182780) in tamoxifen-resistant breast cancer. Lancet. 1995 Jan 7;345(8941):29–30. doi: 10.1016/s0140-6736(95)91156-1. [DOI] [PubMed] [Google Scholar]
  16. Hu X. F., Veroni M., De Luise M., Wakeling A., Sutherland R., Watts C. K., Zalcberg J. R. Circumvention of tamoxifen resistance by the pure anti-estrogen ICI 182,780. Int J Cancer. 1993 Nov 11;55(5):873–876. doi: 10.1002/ijc.2910550529. [DOI] [PubMed] [Google Scholar]
  17. Huynh H. T., Pollak M. Insulin-like growth factor I gene expression in the uterus is stimulated by tamoxifen and inhibited by the pure antiestrogen ICI 182780. Cancer Res. 1993 Dec 1;53(23):5585–5588. [PubMed] [Google Scholar]
  18. Huynh H. T., Tetenes E., Wallace L., Pollak M. In vivo inhibition of insulin-like growth factor I gene expression by tamoxifen. Cancer Res. 1993 Apr 15;53(8):1727–1730. [PubMed] [Google Scholar]
  19. Karey K. P., Sirbasku D. A. Differential responsiveness of human breast cancer cell lines MCF-7 and T47D to growth factors and 17 beta-estradiol. Cancer Res. 1988 Jul 15;48(14):4083–4092. [PubMed] [Google Scholar]
  20. Knabbe C., Lippman M. E., Wakefield L. M., Flanders K. C., Kasid A., Derynck R., Dickson R. B. Evidence that transforming growth factor-beta is a hormonally regulated negative growth factor in human breast cancer cells. Cell. 1987 Feb 13;48(3):417–428. doi: 10.1016/0092-8674(87)90193-0. [DOI] [PubMed] [Google Scholar]
  21. Lien E. A., Johannessen D. C., Aakvaag A., Lønning P. E. Influence of tamoxifen, aminoglutethimide and goserelin on human plasma IGF-I levels in breast cancer patients. J Steroid Biochem Mol Biol. 1992 Mar;41(3-8):541–543. doi: 10.1016/0960-0760(92)90380-2. [DOI] [PubMed] [Google Scholar]
  22. Litherland S., Jackson I. M. Antioestrogens in the management of hormone-dependent cancer. Cancer Treat Rev. 1988 Sep;15(3):183–194. doi: 10.1016/0305-7372(88)90002-3. [DOI] [PubMed] [Google Scholar]
  23. Lønning P. E., Hall K., Aakvaag A., Lien E. A. Influence of tamoxifen on plasma levels of insulin-like growth factor I and insulin-like growth factor binding protein I in breast cancer patients. Cancer Res. 1992 Sep 1;52(17):4719–4723. [PubMed] [Google Scholar]
  24. McPherson G. A. Analysis of radioligand binding experiments. A collection of computer programs for the IBM PC. J Pharmacol Methods. 1985 Nov;14(3):213–228. doi: 10.1016/0160-5402(85)90034-8. [DOI] [PubMed] [Google Scholar]
  25. Mullick A., Chambon P. Characterization of the estrogen receptor in two antiestrogen-resistant cell lines, LY2 and T47D. Cancer Res. 1990 Jan 15;50(2):333–338. [PubMed] [Google Scholar]
  26. Muss H. B. Endocrine therapy for advanced breast cancer: a review. Breast Cancer Res Treat. 1992;21(1):15–26. doi: 10.1007/BF01811960. [DOI] [PubMed] [Google Scholar]
  27. Nakanishi Y., Mulshine J. L., Kasprzyk P. G., Natale R. B., Maneckjee R., Avis I., Treston A. M., Gazdar A. F., Minna J. D., Cuttitta F. Insulin-like growth factor-I can mediate autocrine proliferation of human small cell lung cancer cell lines in vitro. J Clin Invest. 1988 Jul;82(1):354–359. doi: 10.1172/JCI113594. [DOI] [PMC free article] [PubMed] [Google Scholar]
  28. Nayfield S. G., Karp J. E., Ford L. G., Dorr F. A., Kramer B. S. Potential role of tamoxifen in prevention of breast cancer. J Natl Cancer Inst. 1991 Oct 16;83(20):1450–1459. doi: 10.1093/jnci/83.20.1450. [DOI] [PubMed] [Google Scholar]
  29. Newton C. J., Buric R., Trapp T., Brockmeier S., Pagotto U., Stalla G. K. The unliganded estrogen receptor (ER) transduces growth factor signals. J Steroid Biochem Mol Biol. 1994 Apr;48(5-6):481–486. doi: 10.1016/0960-0760(94)90197-x. [DOI] [PubMed] [Google Scholar]
  30. Osborne C. K., Arteaga C. L. Autocrine and paracrine growth regulation of breast cancer: clinical implications. Breast Cancer Res Treat. 1990 Jan;15(1):3–11. doi: 10.1007/BF01811884. [DOI] [PubMed] [Google Scholar]
  31. Osborne C. K., Wiebe V. J., McGuire W. L., Ciocca D. R., DeGregorio M. W. Tamoxifen and the isomers of 4-hydroxytamoxifen in tamoxifen-resistant tumors from breast cancer patients. J Clin Oncol. 1992 Feb;10(2):304–310. doi: 10.1200/JCO.1992.10.2.304. [DOI] [PubMed] [Google Scholar]
  32. Parker M. G. Action of "pure" antiestrogens in inhibiting estrogen receptor action. Breast Cancer Res Treat. 1993;26(2):131–137. doi: 10.1007/BF00689686. [DOI] [PubMed] [Google Scholar]
  33. Powles T. J., Tillyer C. R., Jones A. L., Ashley S. E., Treleaven J., Davey J. B., McKinna J. A. Prevention of breast cancer with tamoxifen--an update on the Royal Marsden Hospital pilot programme. Eur J Cancer. 1990;26(6):680–684. doi: 10.1016/0277-5379(90)90116-b. [DOI] [PubMed] [Google Scholar]
  34. Pratt S. E., Pollak M. N. Estrogen and antiestrogen modulation of MCF7 human breast cancer cell proliferation is associated with specific alterations in accumulation of insulin-like growth factor-binding proteins in conditioned media. Cancer Res. 1993 Nov 1;53(21):5193–5198. [PubMed] [Google Scholar]
  35. Reed M. J., Christodoulides A., Koistinen R., Seppälä M., Teale J. D., Ghilchik M. W. The effect of endocrine therapy with medroxyprogesterone acetate, 4-hydroxyandrostenedione or tamoxifen on plasma concentrations of insulin-like growth factor (IGF)-I, IGF-II and IGFBP-1 in women with advanced breast cancer. Int J Cancer. 1992 Sep 9;52(2):208–212. doi: 10.1002/ijc.2910520209. [DOI] [PubMed] [Google Scholar]
  36. Rosen N., Yee D., Lippman M. E., Paik S., Cullen K. J. Insulin-like growth factors in human breast cancer. Breast Cancer Res Treat. 1991 May;18 (Suppl 1):S55–S62. doi: 10.1007/BF02633529. [DOI] [PubMed] [Google Scholar]
  37. Rutqvist L. E., Cedermark B., Glas U., Johansson H., Nordenskjöld B., Skoog L., Somell A., Theve T., Friberg S., Askergren J. The Stockholm trial on adjuvant tamoxifen in early breast cancer. Correlation between estrogen receptor level and treatment effect. Breast Cancer Res Treat. 1987 Dec;10(3):255–266. doi: 10.1007/BF01805762. [DOI] [PubMed] [Google Scholar]
  38. Stewart A. J., Johnson M. D., May F. E., Westley B. R. Role of insulin-like growth factors and the type I insulin-like growth factor receptor in the estrogen-stimulated proliferation of human breast cancer cells. J Biol Chem. 1990 Dec 5;265(34):21172–21178. [PubMed] [Google Scholar]
  39. Stewart A. J., Westley B. R., May F. E. Modulation of the proliferative response of breast cancer cells to growth factors by oestrogen. Br J Cancer. 1992 Oct;66(4):640–648. doi: 10.1038/bjc.1992.330. [DOI] [PMC free article] [PubMed] [Google Scholar]
  40. Thompson E. W., Reich R., Shima T. B., Albini A., Graf J., Martin G. R., Dickson R. B., Lippman M. E. Differential regulation of growth and invasiveness of MCF-7 breast cancer cells by antiestrogens. Cancer Res. 1988 Dec 1;48(23):6764–6768. [PubMed] [Google Scholar]
  41. Vignon F., Bouton M. M., Rochefort H. Antiestrogens inhibit the mitogenic effect of growth factors on breast cancer cells in the total absence of estrogens. Biochem Biophys Res Commun. 1987 Aug 14;146(3):1502–1508. doi: 10.1016/0006-291x(87)90819-9. [DOI] [PubMed] [Google Scholar]
  42. Vignon F., Capony F., Chambon M., Freiss G., Garcia M., Rochefort H. Autocrine growth stimulation of the MCF 7 breast cancer cells by the estrogen-regulated 52 K protein. Endocrinology. 1986 Apr;118(4):1537–1545. doi: 10.1210/endo-118-4-1537. [DOI] [PubMed] [Google Scholar]
  43. Wakeling A. E. Comparative studies on the effects of steroidal and nonsteroidal oestrogen antagonists on the proliferation of human breast cancer cells. J Steroid Biochem. 1989;34(1-6):183–188. doi: 10.1016/0022-4731(89)90081-2. [DOI] [PubMed] [Google Scholar]
  44. Wakeling A. E., Dukes M., Bowler J. A potent specific pure antiestrogen with clinical potential. Cancer Res. 1991 Aug 1;51(15):3867–3873. [PubMed] [Google Scholar]
  45. Wiseman L. R., Johnson M. D., Wakeling A. E., Lykkesfeldt A. E., May F. E., Westley B. R. Type I IGF receptor and acquired tamoxifen resistance in oestrogen-responsive human breast cancer cells. Eur J Cancer. 1993;29A(16):2256–2264. doi: 10.1016/0959-8049(93)90218-5. [DOI] [PubMed] [Google Scholar]
  46. Wolf D. M., Jordan V. C. William L. McGuire Memorial Symposium. Drug resistance to tamoxifen during breast cancer therapy. Breast Cancer Res Treat. 1993;27(1-2):27–40. doi: 10.1007/BF00683191. [DOI] [PubMed] [Google Scholar]
  47. Yee D., Favoni R. E., Lippman M. E., Powell D. R. Identification of insulin-like growth factor binding proteins in breast cancer cells. Breast Cancer Res Treat. 1991 Mar;18(1):3–10. doi: 10.1007/BF01975437. [DOI] [PubMed] [Google Scholar]
  48. Yee D., Paik S., Lebovic G. S., Marcus R. R., Favoni R. E., Cullen K. J., Lippman M. E., Rosen N. Analysis of insulin-like growth factor I gene expression in malignancy: evidence for a paracrine role in human breast cancer. Mol Endocrinol. 1989 Mar;3(3):509–517. doi: 10.1210/mend-3-3-509. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Pharmacology are provided here courtesy of The British Pharmacological Society

RESOURCES